First, we measured total cfDNA using a ddPCR assay targeting the ACTB gene, which does not differentiate tumor-derived DNA from non-tumor-derived DNA, potentially introducing confounding factors from non-malignant sources and limiting specificity compared to mutation-specific ctDNA assays. This evidence concerns the gene ACTB and neoplasm.